Paratek Pharmaceuticals

Patent cliffs & loss of exclusivity

A biopharmaceutical company developing and commercializing therapies based on tetracycline chemistry for the treatment of infectious and serious diseases

Company

AngelList URLhttps://angel.co/paratek-pharmaceuticals
Legal NameParatek Pharmaceuticals, Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/paratek-pharmaceuticals
Facebook URLhttps://www.facebook.com/paratekpharma/
Full Address75 Park Plaza 3rd Floor Boston, MA 02116, US
LinkedIn URLhttps://www.linkedin.com/company/paratek-pharmaceuticals-inc-
Pitchbook URLhttps://pitchbook.com/profiles/company/10837-18

3 upcoming patent cliffs

DrugIngredientTypeCliff
  1. XHANCEFLUTICASONE PROPIONATESmall mol.Feb 2036
  2. NUZYRAOMADACYCLINE TOSYLATESmall mol.Oct 2037
  3. NUZYRAOMADACYCLINE TOSYLATESmall mol.Oct 2037

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.